The list of emerging and reemerging pathogens that cause neurologic disease is expanding. Various factors, including population growth and a rise in international travel, have contributed to the spread of pathogens to previously nonendemic regions. Recent advances in diagnostic methods have led to the identification of novel pathogens responsible for infections of the central nervous system. Furthermore, new issues have arisen surrounding established infections, particularly in an increasingly immunocompromised population due to advances in the treatment of rheumatologic disease and in transplant medicine.
SchmidtNJLennetteEHHoHH. An apparently new enterovirus isolated from patients with disease of the central nervous system. J Infect Dis. 1974;129(3):304–309.
2.
MelnickJLTagayaIMagnus VonH. Enteroviruses 69, 70, and 71. Intervirology. 1974;4(6):369–370.
3.
HoMChenERHsuKH. An epidemic of Enterovirus 71 infection in Taiwan. N Engl J Med. 1999;341(13):929–935.
4.
YangFRenLXiongZ. Enterovirus 71 outbreak in the People’s Republic of China in 2008. J Clin Microbiol. 2009;47(7):2351–2352. doi:10.1128/JCM.00563-09.
BadranSAMidgleySAndersenPBöttigerB. Clinical and virological features of enterovirus 71 infections in Denmark, 2005 to 2008. Scand J Infect Dis. 2011;43(8):642–648. doi:10.3109/00365548.2011.577094.
7.
Perez-VelezCMAndersonMSRobinsonCC. Outbreak of neurologic enterovirus type 71 disease: a diagnostic challenge. Clin Infect Dis. 2007;45(8):950–957. doi:10.1086/521895.
8.
ChanLGParasharUDLyeMS. Deaths of children during an outbreak of hand, foot, and mouth disease in Sarawak, Malaysia: clinical and pathological characteristics of the disease. Clin Infect Dis. 2000;31(3):678–683. doi:10.1086/314032.
9.
OoiMHWongSCPodinY. Human enterovirus 71 disease in Sarawak, Malaysia: a prospective clinical, virological, and molecular epidemiological study. Clin Infect Dis. 2007;44(5):646–656. doi:10.1086/511073.
10.
HuangCCLiuCCChangYCChenCYWangSTYehTF. Neurologic complications in children with enterovirus 71 infection. N Engl J Med. 1999;341(13):936–942. doi:10.1056/NEJM199909233411302.
11.
WangSMLiuCCTsengHW. Clinical spectrum of enterovirus 71 infection in children in southern Taiwan, with an emphasis on neurological complications. Clin Infect Dis. 1999;29(1):184–190. doi:10.1086/520149.
12.
MaEChanKCChengPWongCChuangSK. The enterovirus 71 epidemic in 2008—public health implications for Hong Kong. Int J Infect Dis. 2010;14(9): e775–80. doi:10.1016/j.ijid.2010.02.2265.
13.
GilbertGLDicksonKEWatersMJKennettMLLandSASneddonM. Outbreak of Enterovirus 71 infection in Victoria, Australia, with a high incidence of neurologic involvement. Pediatr Infect Dis J. 1988;7(7):484–488.
14.
KomatsuHShimizuYTakeuchiYIshikoHTakadaH. Outbreak of severe neurologic involvement associated with Enterovirus 71 infection. Pediatr Neurol. 1999;20(1):17–23.
15.
SamudaGMChangWKYeungCYTangPS. Monoplegia caused by Enterovirus 71: an outbreak in Hong Kong. Pediatr Infect Dis J. 1987;6(2):206–208.
16.
McMinnPStratovINagarajanLDavisS. Neurological manifestations of Enterovirus 71 infection in children during an outbreak of hand, foot, and mouth disease in Western Australia. Clin Infect Dis. 2001;32(2):236–242. doi:10.1086/318454.
17.
AlamMMKhurshidAShaukatSSharifS. Identification of human parechovirus genotype, HPeV-12, in a paralytic child with diarrhea. J Clin Virol. 2012;55(4):339–342.
18.
HarvalaHWolthersKCSimmondsP. Parechoviruses in children: understanding a new infection. Curr Opin Infect Dis. 2010;23(3):224–230.
19.
SelvaranganRNzabiMSelvarajuSBKetterPCarpenterCHarrisonCJ. Human parechovirus 3 causing sepsis-like illness in children from midwestern United States. Pediatr Infect Dis J. 2011;30(3):238–242. doi:10.1097/INF.0b013e3181fbefc8.
20.
Verboon-MaciolekMAKredietTGGerardsLJde VriesLSGroenendaalFvan LoonAM. Severe neonatal parechovirus infection and similarity with enterovirus infection. Pediatr Infect Dis J. 2008;27(3):241–245. doi:10.1097/INF.0b013e31815c1b07.
21.
PetersenLRBraultACNasciRS. West Nile virus: review of the literature. JAMA. 2013;310(3):308–315. doi:10.1001/jama.2013.8042.
22.
SmithburnKCHughesTPBurkeAWPaulJH. A neurotropic virus isolated from the blood of a native of Uganda. Am J Trop Med Hyg. 1940;1(4):471–492.
23.
NashDMostashariFFineA. The outbreak of West Nile virus infection in the New York City area in 1999. N Engl J Med. 2001;344(24):1807–1814. doi:10.1056/NEJM200106143442401.
24.
Centers for Disease Control and Prevention CDC. West Nile virus and other arboviral diseases—United States, 2012. MMWR Morb Mortal Wkly Rep. 2013;62(25):513–517.
25.
KuehnBM. Record heat may have contributed to a banner year for West Nile virus. JAMA. 2012;308(18):1846–1848.
26.
ArnoldC. West Nile virus bites back. Lancet Neurol. 2012;11(12):1023–1024. doi:10.1016/S1474-4422(12)70278-8.
27.
ZouSFosterGADoddRYPetersenLRStramerSL. West Nile fever characteristics among viremic persons identified through blood donor screening. J Infect Dis. 2010;202(9):1354–1361. doi:10.1086/656602.
28.
DavisLEDeBiasiRGoadeDE. West Nile virus neuroinvasive disease. Ann Neurol. 2006;60(3):286–300. doi:10.1002/ana.20959.
29.
LindseyNPStaplesJELehmanJAFischerM. Medical risk factors for severe West Nile virus disease, United States, 2008-2010. Am J Trop Med Hyg. 2012;87(1):179–184. doi:10.4269/ajtmh.2012.12-0113.
30.
BuschMPKleinmanSHToblerLH. Virus and antibody dynamics in acute West Nile virus infection. J Infect Dis. 2008;198(7):984–993. doi:10.1086/591467.
31.
RoehrigJTNashDMaldinB. Persistence of virus-reactive serum immunoglobulin m antibody in confirmed West Nile virus encephalitis cases. Emerg Infect Dis. 2003;9(3):376–379. doi:10.3201/eid0903.020531.
32.
KapoorHSignsKSomselPDownesFPClarkPAMasseyJP. Persistence of West Nile virus (WNV) IgM antibodies in cerebrospinal fluid from patients with CNS disease. J Clin Virol. 2004;31(4):289–291. doi:10.1016/j.jcv.2004.05.017.
33.
Centers for Disease Control and Prevention. Powassan Virus. Atlanta, GA: CDC. http://www.cdc.gov/powassan/. Updated August 8, 2013. Accessed February 25, 2014.
CampbellGLHillsSLFischerM. Estimated global incidence of Japanese encephalitis: a systematic review. Bull World Health Organ. 2011;89(10):766. doi:10.2471/BLT.10.085233.
36.
Centers for Disease Control and Prevention. Japanese encephalitis surveillance and immunization—Asia and the Western Pacific, 2012. MMWR Morb Mortal Wkly Rep. 2013;62(33):658–662.
37.
SolomonTVaughnDW. Pathogenesis and clinical features of Japanese encephalitis and West Nile virus infections. Curr Top Microbiol Immunol. 2002;267:171–194.
38.
SolomonTKneenRDungNM. Poliomyelitis-like illness due to Japanese encephalitis virus. Lancet. 1998;351(9109):1094–1097. doi:10.1016/S0140-6736(97)07509-0.
39.
SolomonTDungNMKneenRGainsboroughMVaughnDWKhanhVT. Japanese encephalitis. J Neurol Neurosurg Psychiatr. 2000;68(4):405–415.
40.
FischerMLindseyNStaplesJEHillsS. Japanese encephalitis vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010;59(RR-1):1–27.
41.
HillsSLGriggsACFischerM. Japanese Encephalitis in travelers from non-endemic countries, 1973-2008. Am J Trop Med Hyg. 2010;82(5):930–936. doi:10.4269/ajtmh.2010.09-0676.
42.
HillsSLStolteyJMartínezD. A case series of three US adults with Japanese encephalitis, 2010-2012 [published online May 26, 2014]. J TravMed. 2014.
43.
MansfieldKLJohnsonNPhippsLPStephensonJRFooksARSolomonT. Tick-borne encephalitis virus—a review of an emerging zoonosis. J Gen Virol. 2009;90(8):1781–1794. doi:10.1099/vir.0.011437-0.
44.
SussJ. Tick-borne encephalitis in Europe and beyond—the epidemiological situation as of 2007. Euro Surveill. 2008;13(26).
45.
BogovicPLotric-FurlanSStrleF. What tick-borne encephalitis may look like: clinical signs and symptoms. Travel Med Infect Dis. 2010;8(4):246–250. doi:10.1016/j.tmaid.2010.05.011.
46.
Centers for Disease Control and Prevention CDC. Tick-borne encephalitis among U.S. travelers to Europe and Asia—2000-2009. MMWR Morb Mortal Wkly Rep. 2010;59(11):335–338.
47.
CharrelRNGallianPNavarro-MariJM. Emergence of Toscana virus in Europe. Emerg Infect Dis. 2005;11(11):1657–1663. doi:10.3201/eid1111.050869.
48.
BraitoACiufoliniMGPippiL. Phlebotomus-transmitted Toscana virus infections of the central nervous system: a seven-year experience in Tuscany. Scand J Infect Dis. 1998;30(5):505–508.
49.
FrancisciDPapiliRCamanniG. Evidence of Toscana virus circulation in Umbria: first report. Eur J Epidemiol. 2003;18(5):457–459.
50.
EitremRStylianouMNiklassonB. High prevalence rates of antibody to three sandfly fever viruses (Sicilian, Naples, and Toscana) among Cypriots. Epidemiol Infect. 1991;107(3):685–691.
51.
Mendoza-MonteroJGámez-RuedaMINavarro-MaríJMla Rosa-Fraile deMOyonarte-GómezS. Infections due to sandfly fever virus serotype Toscana in Spain. Clin Infect Dis. 1998;27(3):434–436.
52.
KayMKGibneyKBRiedoFXKosoyOLLanciottiRSLambertAJ. Toscana virus infection in American traveler returning from Sicily, 2009. Emerg Infect Dis. 2010;16(9):1498–1500. doi:10.3201/eid1609.100505.
53.
JaijakulSAriasCAHossainMArduinoRCWoottonSHHasbunR. Toscana meningoencephalitis: a comparison to other viral central nervous system infections. J Clin Virol. 2012;55(3):204–208. doi:10.1016/j.jcv.2012.07.007.
54.
RobinsonMC. An epidemic of virus disease in Southern Province, Tanganyika Territory, in 1952-53. I. Clinical features. Trans R Soc Trop Med Hyg. 1955;49(1):28–32.
55.
World Health Organization. Outbreak and spread of chikungunya. Wkly Epidemiol Rec. 2007;82(47):409–415.
56.
StaplesJEBreimanRFPowersAM. Chikungunya fever: an epidemiological review of a re-emerging infectious disease. Clin Infect Dis. 2009;49(6):942–948. doi:10.1086/605496.
57.
GibneyKBFischerMPrinceHE. Chikungunya fever in the United States: a fifteen year review of cases. Clin Infect Dis. 2011;52(5):e121–e126. doi:10.1093/cid/ciq214.
58.
RezzaGNicolettiLAngeliniR. Infection with chikungunya virus in Italy: an outbreak in a temperate region. Lancet. 2007;370(9602):1840–1846. doi:10.1016/S0140-6736(07)61779-6.
RenaultPSoletJLSissokoD. A major epidemic of chikungunya virus infection on Reunion Island, France, 2005-2006. Am J Trop Med Hyg. 2007;77(4):727–731.
61.
BorgheriniGPoubeauPStaikowskyF. Outbreak of chikungunya on reunion island: early clinical and laboratory features in 157 adult patients. Clin Infect Dis. 2007;44(11):1401–1407.
SinghSSManimundaSPSugunanAPSahinaVijayachariP. Four cases of acute flaccid paralysis associated with chikungunya virus infection. Epidemiol Infect. 2008;136(9):1277–1280. doi:10.1017/S0950268807009739.
64.
ChusriSSiripaitoonPHirunpatSSilpapojakulK. Case reports of neuro-chikungunya in southern Thailand. Am J Trop Med Hyg. 2011;85(2):386–389. doi:10.4269/ajtmh.2011.10-0725.
65.
LarrieuSPouderouxNPistoneT. Factors associated with persistence of arthralgia among chikungunya virus-infected travellers: report of 42 French cases. J Clin Virol. 2010;47(1):85–88. doi:10.1016/j.jcv.2009.11.014.
66.
de AndradeDCJeanSClavelouPDallelRBouhassiraD. Chronic pain associated with the chikungunya fever: long lasting burden of an acute illness. BMC Infect Dis. 2010;10:31. doi:10.1186/1471-2334-10-31.
67.
ChewMHArguinPMShayDK. Risk factors for Nipah virus infection among abattoir workers in Singapore. J Infect Dis. 2000;181(5):1760–1763. doi:10.1086/315443.
68.
WongKT. Emerging epidemic viral encephalitides with a special focus on henipaviruses. Acta Neuropathol. 2010;120(3):317–325. doi:10.1007/s00401-010-0720-z.
69.
MontgomeryJMHossainMJGurleyE. Risk factors for Nipah virus Encephalitis in Bangladesh. Emerg Infect Dis. 2008;14(10):1526. doi:10.3201/eid1410.060507.
70.
GurleyESMontgomeryJMHossainMJ. Person-to-person transmission of Nipah virus in a Bangladeshi community. Emerg Infect Dis. 2007;13(7):1031–1037. doi:10.3201/eid1307.061128.
71.
MahalingamSHerreroLJPlayfordEG. Hendra virus: an emerging paramyxovirus in Australia. Lancet Infect Dis. 2012;12(10):799–807. doi:10.1016/S1473-3099(12)70158-5.
72.
LeVTvan DoornHRNghiaHDT. Identification of a new cyclovirus in cerebrospinal fluid of patients with acute central nervous system infections. MBio. 2013;4(3):e00231–13. doi:10.1128/mBio.00231-13.
73.
SmitsSLZijlstraEEvan HellemondJJ. Novel cyclovirus in human cerebrospinal fluid, Malawi, 2010-2011. Emerg Infect Dis. 2013;19(9):1511. doi:10.3201/eid1909.130404.
74.
YozwiakNLSkewes-CoxPStengleinMDBalmasedaAHarrisEDeRisiJL. Virus identification in unknown tropical febrile illness cases using deep sequencing. PLoS Negl Trop Dis. 2012;6(2):e1485. doi:10.1371/journal.pntd.0001485.
75.
GugliottaJLGoethertHKBerardiVPTelfordSR. Meningoencephalitis from Borrelia miyamotoi in an immunocompromised patient. N Engl J Med. 2013;368(3):240–245. doi:10.1056/NEJMoa1209039.
76.
FukunagaMTakahashiYTsurutaY. Genetic and phenotypic analysis of Borrelia miyamotoi sp. nov., isolated from the ixodid tick ixodes persulcatus, the vector for Lyme disease in Japan. Int J of Syst Bacteriol. 1995;45(4)804–810.
77.
RichterDSchleeDBMatuschkaFR. Relapsing fever-like spirochetes infecting European vector tick of Lyme disease agent. Emerg Infect Dis. 2003;9(6):697–701. doi:10.3201/eid0906.020459.
78.
BarbourAGBunikisJTravinskyB. Niche partitioning of Borrelia burgdorferi and Borrelia miyamotoi in the same tick vector and mammalian reservoir species. Am J Trop Med Hyg. 2009;81(6):1120–1131. doi:10.4269/ajtmh.2009.09-0208.
79.
KrausePJNarasimhanSWormserGP. Human Borrelia miyamotoi infection in the United States. N Engl J Med. 2013;368(3):291–293. doi:10.1056/NEJMc1215469.
ThigpenMCWhitneyCGMessonnierNE. Bacterial meningitis in the United States, 1998-2007. N Engl J Med. 2011;364(21):2016–2025. doi:10.1056/NEJMoa1005384.
82.
CohnACMacNeilJRHarrisonLH. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis. 2010;50(2):184–191. doi:10.1086/649209.
83.
PolandGA. Prevention of meningococcal disease: current use of polysaccharide and conjugate vaccines. Clin Infect Dis. 2010;50(s2):S45–S53. doi:10.1086/648964.
84.
Centers for Disease Control and Prevention CDC. Notes from the field: serogroup C invasive meningococcal disease among men who have sex with men— New York City, 2010-2012. MMWR Morb Mortal Wkly Rep. 2013;61(51-52):1048.
85.
SimonMSWeissDGulickRM. Invasive meningococcal disease in men who have sex with men. Ann Intern Med. 2013;159(4):300–301. doi:10.7326/0003-4819-159-4-201308200-00674.
86.
BrooksRWoodsCWBenjaminDKRosensteinNE. Increased case-fatality rate associated with outbreaks of Neisseria meningitidis infection, compared with sporadic meningococcal disease, in the United States, 1994-2002. Clin Infect Dis. 2006;43(1):49–54. doi:10.1086/504804.
87.
Centers for Disease Control and Prevention CDC. National and state vaccination coverage among adolescents aged 13-17 years—United States, 2012. MMWR Morb Mortal Wkly Rep. 2013;62(34):685–693.
GranoffDM. Review of meningococcal group B vaccines. Clin Infect Dis. 2010;50(Suppl 2):S54–S65.
91.
MoxonRSnapeMD. The price of prevention: what now for immunisation against meningococcus B?Lancet. 2013;382(9890):369–370. doi:10.1016/S0140-6736(13)61572-X.
92.
HarrisJRLockhartSRDebessE. Cryptococcus gattii in the United States: clinical aspects of infection with an emerging pathogen. Clin Infect Dis. 2011;53(12):1188–1195. doi:10.1093/cid/cir723.
93.
MacDougallLKiddSEGalanisE. Spread of Cryptococcus gattii in British Columbia, Canada, and detection in the Pacific Northwest, USA. Emerg Infect Dis. 2007;13(1):42–50. doi:10.3201/eid1301.060827.
94.
HarrisJRLockhartSRSondermeyerG. Cryptococcus gattii infections in multiple states outside the US Pacific Northwest. Emerg Infect Dis. 2013;19(10):1621–1627. doi:10.3201/eid1910.130441.
95.
IversonSAChillerTBeekmannSPolgreenPMHarrisJ. Recognition and diagnosis of Cryptococcus gattii infections in the United States. Emerg Infect Dis. 2012;18(6):1012–1015. doi:10.3201/eid1806.111228.
96.
MitchellDHSorrellTCAllworthAM. Cryptococcal disease of the CNS in immunocompetent hosts: influence of cryptococcal variety on clinical manifestations and outcome. Clin Infect Dis. 1995;20(3):611–616.
97.
ChenSCASlavinMAHeathCH. Clinical manifestations of Cryptococcus gattii infection: determinants of neurological sequelae and death. Clin Infect Dis. 2012;55(6)789–798.
98.
Kwon-ChungKJBennettJE. Epidemiologic differences between the two varieties of Cryptococcus neoformans. Am J Epidemiol. 1984;120(1):123–130.
99.
VisvesvaraGS. Infections with free-living amebae. Handb Clin Neurol. 2013;114:153–168. doi:10.1016/B978-0-444-53490-3.00010-8.
100.
VisvesvaraGSSriramRQvarnstromY. Paravahlkampfia francinae n. sp. masquerading as an agent of primary amoebic meningoencephalitis. J Eukaryot Microbiol. 2009;56(4):357–366. doi:10.1111/j.1550-7408.2009.00410.x.
101.
KembleSKLynfieldRDeVriesAS. Fatal Naegleria fowleri infection acquired in Minnesota: possible expanded range of a deadly thermophilic organism. Clin Infect Dis. 2012;54(6):805–809. doi:10.1093/cid/cir961.
102.
YoderJSStraif-BourgeoisSRoySL. Primary amebic meningoencephalitis deaths associated with sinus irrigation using contaminated tap water. Clin Infect Dis. 2012;55(9):e79–e85. doi:10.1093/cid/cis626.
103.
Centers for Disease Control and Prevention. Primary Amebic Meningoencephalitis (PAM): Sources of Infection and Risk Factors. Atlanta, GA: CDC. http://www.cdc.gov/parasites/naegleria/infection-sources.html. Updated November 14, 2013. Accessed February 20, 2014.
JainRPrabhakarSModiMBhatiaRSehgalR. Naegleria meningitis: a rare survival. Neurol India. 2002;50(4):470–472.
106.
LacknerPBeerRBroessnerG. Acute granulomatous acanthamoeba encephalitis in an immunocompetent patient. Neurocrit Care. 2010;12(1):91–94. doi:10.1007/s12028-009-9291-z.
107.
WebsterDUmarIKolyvasG. Treatment of granulomatous amoebic encephalitis with voriconazole and miltefosine in an immunocompetent soldier. Am J Trop MedHyg. 2012;87(4):715–718.
108.
ReddyRVijayasaradhiMUppinMSChallaSJabeenABorghainR. Acanthamoeba meningoencephalitis in an immunocompetent patient: an autopsy case report. Neuropathology. 2011;31(2):183–187. doi:10.1111/j.1440-1789.2010.01151.x.
109.
BakardjievAAzimiPHAshouriN. Amebic encephalitis caused by Balamuthia mandrillaris: report of four cases. Pediatr Infect Dis J. 2003;22(5):447–453. doi:10.1097/01.inf.0000066540.18671.f8.
110.
SchusterFLYagiSGavaliS. Under the radar: balamuthia amebic encephalitis. Clin Infect Dis. 2009;48(7):879–887. doi:10.1086/597260.
111.
Centers for Disease Control and Prevention. Notes from the field: transplant-transmitted Balamuthia mandrillaris—Arizona, 2010. MMWR Morb Mortal Wkly Rep. 2010;59(36):1182.
112.
Centers for Disease Control and Prevention CDC. Balamuthia mandrillaristransmitted through organ transplantation—Mississippi, 2009. MMWR Morb Mortal Wkly Rep. 2010;59(36):1165–1170.
113.
CopeJRRoySLYoderJSBeachMJ. Improved treatment of granulomatous amebic encephalitis and other infections caused by Balamuthia mandrillaris and Acanthamoeba species. Presented at: Council of State and Territorial Epidemiologists' Annual Conference, Pasadena, CA, June 9-13, 2013.
114.
Centers for Disease Control and Prevention. Investigational drug available directly from CDC for the treatment of infections with free-living amebae. MMWR Morb Mortal Wkly Rep. 2013;62(33):666.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
